Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474949 | 0.77 | HTR1A (0.52) | TDP1L3MBTL1ALDH1A1CYP1A2MAPT | |
| SCHEMBL7736561 | 0.76 | MEN1 (0.50) | KMT2AALDH1A1SIGMAR1MEN1CYP1A2 | |
| SCHEMBL27435293 | 0.76 | MAPT (0.50) | KMT2ATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1471179 | 0.75 | CYP1A2 (0.49) | KMT2ATDP1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL16809212 | 0.73 | ALDH1A1 (0.49) | KMT2ATDP1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL8796187 | 0.73 | CYP1A2 (0.47) | KMT2ATDP1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL14452079 | 0.72 | DPP4 (0.43) | KMT2AL3MBTL1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL30100732 | 0.71 | ALDH1A1 (0.53) | KMT2ATDP1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL30487743 | 0.71 | ALDH1A1 (0.53) | KMT2ATDP1ALDH1A1MEN1CYP1A2 | |
| SCHEMBL888030 | 0.71 | ALDH1A1 (0.53) | KMT2ATDP1ALDH1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | disclosed |
| CN-1671672-A | Aryl-substituted benzimidazoles and their use as sodium channel blockers | EURO CELTIQUE SA (LU) | 2005-09-21 | — | — | CN | disclosed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | disclosed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | disclosed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | CACNA1S, CACNA1I, SCN1A | KMT2A 2665/4885TDP1 378/4885L3MBTL1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.